What's Actually Happening: Two Programs, Two Timelines
CMS (the Centers for Medicare & Medicaid Services) has structured this in two phases. Understanding the difference matters because they operate under completely different rules.
Program 1: BALANCE Model (Medicaid)
BALANCE — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — is a voluntary model that allows state Medicaid agencies to cover GLP-1 medications for weight management. CMS negotiated directly with Eli Lilly and Novo Nordisk for lower drug prices, and participating states can now offer coverage to Medicaid-eligible patients.
States can join on a rolling basis from May 2026 through January 2027. The model runs through December 2031. As of January 2026, only 13 states provided any Medicaid coverage for obesity drugs — down from 16 states the year before, largely due to budget pressures. BALANCE aims to reverse that trend by reducing the financial burden on state budgets through negotiated pricing.
Program 2: Medicare GLP-1 Bridge (Medicare Part D)
This is the more concrete, more immediate program for men over 65. The Medicare GLP-1 Bridge is a nationwide demonstration that provides eligible Medicare Part D beneficiaries with access to Wegovy (semaglutide) and Zepbound (tirzepatide) at a copay of $50 per month.
The Bridge program launches July 1, 2026, and has been extended through December 31, 2027. On April 21, 2026, CMS announced that the BALANCE Model will not be implemented in Medicare Part D in 2027 as originally planned — instead, the Bridge program will serve as the primary access pathway through at least the end of 2027.
This is important: the Bridge program operates outside the normal Part D benefit structure. Your Part D plan doesn't need to opt in. If you're enrolled in a Medicare Part D plan and meet the eligibility criteria, you can access these drugs through the demonstration regardless of your specific plan.
The Timeline at a Glance
BALANCE launches in Medicaid
States begin joining on a rolling basis. Coverage depends on state participation and manufacturer negotiations.
Medicare GLP-1 Bridge goes live
Eligible Medicare Part D beneficiaries can access Wegovy and Zepbound at $50/month copay. Nationwide — no plan opt-in required.
Last entry window for Medicaid states
Final deadline for state Medicaid agencies to join BALANCE. Medicare Part D BALANCE launch postponed — Bridge extended instead.
Medicare Bridge currently set to expire
May be extended again depending on CMS evaluation of outcomes data.
BALANCE Model (Medicaid) ends
CMS will evaluate results to determine if the model becomes permanent policy.
Who Qualifies for the Medicare Bridge?
According to CMS FAQs released in March 2026, eligibility requires three things:
1. You must be enrolled in a Medicare Part D plan. This includes standalone Prescription Drug Plans (PDPs) and Medicare Advantage plans with drug coverage (MA-PD).
2. Your prescriber must submit a prior authorization request attesting that the medication is being prescribed for weight reduction and ongoing maintenance.
3. You must meet one of three clinical categories related to BMI and other diagnostic criteria. CMS hasn't published the exact thresholds publicly in plain language yet, but the general framework follows FDA labeling: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, high blood pressure, high cholesterol, cardiovascular disease, sleep apnea).
What Drugs Are Covered?
The Medicare GLP-1 Bridge covers two brand-name medications:
| Drug | Active Ingredient | Manufacturer | Your Cost (Bridge) | Retail Cash Price |
|---|---|---|---|---|
| Wegovy | Semaglutide | Novo Nordisk | $50/mo | $1,349/mo retail |
| Zepbound | Tirzepatide | Eli Lilly | $50/mo | $1,080/mo retail |
That's a savings of $1,000–$1,300 per month compared to retail pricing. Both manufacturers agreed to provide these drugs at a net price of $245/month to the government, with the patient responsible for only $50 of that.
What's NOT covered: Compounded versions of semaglutide or tirzepatide are not included in the Medicare Bridge or BALANCE Model. This is brand-name only. The program also doesn't cover off-label use of diabetes-indicated GLP-1s (like Ozempic or Mounjaro) for weight loss — only the weight-loss-specific formulations qualify.
What This Means for Younger Men (Under 65)
If you're not on Medicare, the direct impact depends on your situation:
If you're on Medicaid: Check whether your state is participating in BALANCE. Coverage will roll out on a state-by-state basis starting now. Contact your state Medicaid office or ask your provider whether GLP-1 coverage for weight management is available in your state under the BALANCE Model.
If you have private insurance: The BALANCE Model doesn't directly affect commercial insurance. However, the negotiated pricing between CMS and manufacturers creates downward pressure on drug prices across the board. Several major insurers have already begun expanding GLP-1 coverage in response to the federal government's moves, and employer plans are following. KFF data shows 44% of large employers covered weight loss medications in 2024, up from previous years.
If you're paying cash: The telehealth and compounded GLP-1 market remains the most affordable access pathway for men without insurance coverage. Compounded semaglutide through telehealth providers typically runs $149–$299/month — significantly less than retail brand-name pricing, though more than the $50 Medicare Bridge copay.
Sesame Care
FDA-approved brand-name GLP-1 medications with clinical support. May help navigate insurance and Medicare pathways.
Gala
Compounded GLP-1 program at $179/month flat — no dose-dependent pricing increases. For men paying cash without insurance.
The Ripple Effects Men Should Watch
Telehealth provider landscape will shift. As Medicare and Medicaid expand brand-name coverage, the market share of compounded GLP-1 providers could change. Providers that offer both brand-name access and compounded options will have an advantage. Providers that only offer compounded products may need to adapt.
Prior authorization becomes the new bottleneck. Under the Medicare Bridge, your prescriber must submit a PA request for you. This means the quality of your provider — whether they know how to navigate the PA process efficiently — matters more than ever. A 2-minute telehealth intake probably won't cut it.
Lifestyle support is now part of the package. BALANCE explicitly requires evidence-based lifestyle support alongside medication. This isn't just a "take this drug" program — it's designed to combine medication with dietary counseling, physical activity programming, and behavioral support. For men who've been going it alone on GLP-1s, this could actually be a better model.
Employer plans will feel the pressure. When the federal government provides GLP-1 access for Medicare and Medicaid populations at $50/month, private employers who still exclude weight loss drugs will face increasing employee frustration. Expect more large employers to add or expand GLP-1 coverage through 2026 and 2027.
Action Steps: What to Do Right Now
If you're on Medicare Part D: Talk to your prescriber about the GLP-1 Bridge program before July 2026. Ask whether they're prepared to submit the required prior authorization. Make sure your prescriber understands the clinical eligibility categories. The program is nationwide and doesn't require your Part D plan to opt in — but the PA process does require your doctor to act.
If you're on Medicaid: Contact your state Medicaid office and ask whether your state is participating in the BALANCE Model. If your state hasn't joined yet, ask when they plan to apply — the window is open through January 2027.
If you're paying cash and can't wait: Telehealth providers offer compounded GLP-1 medications at a fraction of retail pricing. Flat-rate programs like Gala ($179/month) and monitored programs like Embody ($149 first month, $299 ongoing) provide access now without waiting for government programs to roll out.
If you have private insurance that excludes weight loss drugs: Ask your HR department whether your employer is considering adding GLP-1 coverage. The federal government's moves have made this a more common request, and many employers are reevaluating. You can also explore HSA/FSA coverage — weight loss medications prescribed for a diagnosed medical condition may be eligible expenses.